These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33649485)

  • 21. MARCH2: comparative assessment of therapeutic effects of acarbose and metformin in newly diagnosed type 2 diabetes patients.
    Wang G; Liu J; Yang N; Gao X; Fan H; Xu Y; Yang W
    PLoS One; 2014; 9(8):e105698. PubMed ID: 25148570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive Blood Pressure Lowering in Patients With and Patients Without Type 2 Diabetes: A Pooled Analysis From Two Randomized Trials.
    Brouwer TF; Vehmeijer JT; Kalkman DN; Berger WR; van den Born BH; Peters RJ; Knops RE
    Diabetes Care; 2018 Jun; 41(6):1142-1148. PubMed ID: 29212825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study.
    Jørgensen CH; Gislason GH; Andersson C; Ahlehoff O; Charlot M; Schramm TK; Vaag A; Abildstrøm SZ; Torp-Pedersen C; Hansen PR
    Cardiovasc Diabetol; 2010 Sep; 9():54. PubMed ID: 20843380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
    Ueki K; Sasako T; Okazaki Y; Kato M; Okahata S; Katsuyama H; Haraguchi M; Morita A; Ohashi K; Hara K; Morise A; Izumi K; Ishizuka N; Ohashi Y; Noda M; Kadowaki T;
    Lancet Diabetes Endocrinol; 2017 Dec; 5(12):951-964. PubMed ID: 29079252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dysglycemia and increased left ventricle mass in normotensive patients admitted with a first myocardial infarction: prognostic implications of dysglycemia during 14 years of follow-up.
    Pararajasingam G; Løgstrup BB; Høfsten DE; Christophersen TB; Auscher S; Hangaard J; Egstrup K
    BMC Cardiovasc Disord; 2019 May; 19(1):103. PubMed ID: 31046690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes.
    Engelen SE; van der Graaf Y; Stam-Slob MC; Grobbee DE; Cramer MJ; Kappelle LJ; de Borst GJ; Visseren FLJ; Westerink J;
    Int J Cardiol; 2017 Dec; 248():301-307. PubMed ID: 28802735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.
    Chang CH; Chang YC; Lin JW; Chen ST; Chuang LM; Lai MS
    J Clin Endocrinol Metab; 2015 Mar; 100(3):1121-9. PubMed ID: 25555040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Obes Metab; 2018 Jun; 20(6):1499-1502. PubMed ID: 29424469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
    Keech A; Colquhoun D; Best J; Kirby A; Simes RJ; Hunt D; Hague W; Beller E; Arulchelvam M; Baker J; Tonkin A;
    Diabetes Care; 2003 Oct; 26(10):2713-21. PubMed ID: 14514569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study.
    Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
    Diabetologia; 2011 Jun; 54(6):1308-17. PubMed ID: 21359582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP.
    Buckley LF; Dixon DL; Wohlford GF; Wijesinghe DS; Baker WL; Van Tassell BW
    Diabetes Care; 2017 Dec; 40(12):1733-1738. PubMed ID: 28947569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between Neck Circumference and the Occurrence of Cardiovascular Events in Type 2 Diabetes: Beijing Community Diabetes Study 20 (BCDS-20).
    Yang GR; Yuan MX; Wan G; Zhang XL; Fu HJ; Yuan SY; Zhu LX; Xie RR; Zhang JD; Li YL; Sun YH; Dai QF; Gao DY; Cui XL; Gao JQ; Wang ZM; Chen YJ; Hu DM; Gao J; Bai L
    Biomed Res Int; 2019; 2019():4242304. PubMed ID: 31886212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sulphonylureas monotherapy and risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: A population-based cohort study in China.
    Xu Y; Wang T; Yang Z; Lin H; Shen P; Zhan S
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):635-643. PubMed ID: 32383226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.
    Gæde P; Oellgaard J; Carstensen B; Rossing P; Lund-Andersen H; Parving HH; Pedersen O
    Diabetologia; 2016 Nov; 59(11):2298-2307. PubMed ID: 27531506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
    Hanefeld M; Cagatay M; Petrowitsch T; Neuser D; Petzinna D; Rupp M
    Eur Heart J; 2004 Jan; 25(1):10-6. PubMed ID: 14683737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased risk of subsequent myocardial infarction in patients with type 2 diabetes: a retrospective cohort study using the U.K. General Practice Research Database.
    Liang H; Vallarino C; Joseph G; Manne S; Perez A; Zhang S
    Diabetes Care; 2014; 37(5):1329-37. PubMed ID: 24595635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.